Progression of HIV-associated dementia treated with HAART - PubMed (original) (raw)
Affiliations
- PMID: 11905143
Progression of HIV-associated dementia treated with HAART
Ryan H Dougherty et al. AIDS Read. 2002 Feb.
Abstract
A consecutive series of 96 patients with HIV-associated dementia treated with HAART were studied to identify specific clinical factors associated with an improved response to therapy. The Memorial Sloan-Kettering dementia severity scale and the HIV Dementia Scale were used to assess outcomes. Of 30 patients meeting the inclusion criteria with adequate follow-up, 60% improved neurologically and 40% progressed. There was a trend toward improvement associated with plasma viral suppression, whereas progression was strongly associated with injection drug use history (odds ratio, 13.3). Age, ethnicity, gender, adherence, and predicted CNS penetrance of HAART were not associated with improved outcomes.
Similar articles
- The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
Jevtović Dj, Vanovac V, Veselinović M, Salemović D, Ranin J, Stefanova E. Jevtović Dj, et al. Biomed Pharmacother. 2009 Sep;63(8):561-5. doi: 10.1016/j.biopha.2008.09.015. Epub 2008 Nov 5. Biomed Pharmacother. 2009. PMID: 19026516 - Variable benefit in neuropsychological function in HIV-infected HAART-treated patients.
Cysique LA, Maruff P, Brew BJ. Cysique LA, et al. Neurology. 2006 May 9;66(9):1447-50. doi: 10.1212/01.wnl.0000210477.63851.d3. Neurology. 2006. PMID: 16682686 - HIV dementia: an evolving disease.
McArthur JC. McArthur JC. J Neuroimmunol. 2004 Dec;157(1-2):3-10. doi: 10.1016/j.jneuroim.2004.08.042. J Neuroimmunol. 2004. PMID: 15579274 Review. - Drug treatment for HIV-1-associated dementia.
von Giesen HJ, Arendt G. von Giesen HJ, et al. Curr Opin Investig Drugs. 2002 Nov;3(11):1643-6. Curr Opin Investig Drugs. 2002. PMID: 12476967 Review.
Cited by
- HIV Infection and Related Mental Disorders.
Nosik M, Lavrov V, Svitich O. Nosik M, et al. Brain Sci. 2021 Feb 17;11(2):248. doi: 10.3390/brainsci11020248. Brain Sci. 2021. PMID: 33671125 Free PMC article. Review. - Bioenergetic adaptations to HIV infection. Could modulation of energy substrate utilization improve brain health in people living with HIV-1?
Deme P, Rojas C, Slusher BS, Rais R, Afghah Z, Geiger JD, Haughey NJ. Deme P, et al. Exp Neurol. 2020 May;327:113181. doi: 10.1016/j.expneurol.2020.113181. Epub 2020 Jan 11. Exp Neurol. 2020. PMID: 31930991 Free PMC article. Review. - Central HIV-1 Tat exposure elevates anxiety and fear conditioned responses of male mice concurrent with altered mu-opioid receptor-mediated G-protein activation and β-arrestin 2 activity in the forebrain.
Hahn YK, Paris JJ, Lichtman AH, Hauser KF, Sim-Selley LJ, Selley DE, Knapp PE. Hahn YK, et al. Neurobiol Dis. 2016 Aug;92(Pt B):124-36. doi: 10.1016/j.nbd.2016.01.014. Epub 2016 Feb 1. Neurobiol Dis. 2016. PMID: 26845176 Free PMC article. - A systematic review of the screening accuracy of the HIV Dementia Scale and International HIV Dementia Scale.
Haddow LJ, Floyd S, Copas A, Gilson RJ. Haddow LJ, et al. PLoS One. 2013 Apr 16;8(4):e61826. doi: 10.1371/journal.pone.0061826. Print 2013. PLoS One. 2013. PMID: 23613945 Free PMC article. Review. - Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort.
Sakamoto M, Marcotte TD, Umlauf A, Franklin D Jr, Heaton RK, Ellis RJ, Letendre S, Alexander T, McCutchan JA, Morgan EE, Woods SP, Collier AC, Marra CM, Clifford DB, Gelman BB, McArthur JC, Morgello S, Simpson D, Grant I; CHARTER Group. Sakamoto M, et al. J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):36-42. doi: 10.1097/QAI.0b013e318278ffa4. J Acquir Immune Defic Syndr. 2013. PMID: 23111573 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical